TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s updated 2026 antimicrobial-resistance report estimates that the pathogens it tracks cause 9.7 million infections and 50,800 deaths in the United States each year. Four drug-resistant pathogens are classified as urgent threats; the report also adds new watch-list organisms and downgrades C. difficile to serious.
The CDC’s updated 2026 antimicrobial-resistance report estimates that the pathogens it tracks cause about 9.7 million infections and 50,800 deaths in the United States annually. The agency classifies four drug-resistant pathogens as urgent threats, a top-tier designation signaling a need for aggressive public-health action.
The urgent-threat group includes Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The report ranks 19 pathogens across threat levels described as concerning, serious or urgent, and identifies six additional pathogens on a watch list for potential threats.
The report gives examples of the burden from individual organisms. In 2023, carbapenem-resistant Acinetobacter was linked to 9,497 U.S. hospitalizations and an estimated 817 deaths; carbapenem-resistant Enterobacterales were linked to 14,878 hospitalizations and an estimated 1,252 deaths. These are pathogen-specific figures for 2023, not annual estimates for the full group in the report.
Reported U.S. C. auris cases rose from 48 in 2016 to 4,523 in 2023, according to the supplied report summary. Drug-resistant gonorrhea caused an estimated 787,000 U.S. infections in 2023. The CDC said 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or showed elevated minimum inhibitory concentrations.
Risks for Patients and Care
Antimicrobial resistance can make infections harder to treat, particularly when patients have limited treatment options or are already receiving complex medical care. The Infectious Diseases Society of America says resistant infections can extend hospital stays and raise health-care costs. They can also complicate care such as chemotherapy, organ transplants and surgery, when preventing or treating infection is important.
The report’s combined estimate gives policymakers and health systems a measure of the scale of the problem, while its threat categories identify organisms the CDC considers priorities for action. The figures do not mean that every listed infection is resistant to every available drug, or that all people face the same risk. Some, including Acinetobacter and Enterobacterales, pose particular concerns in hospitals and nursing homes; the CDC report also identifies drug resistance as a challenge for treating gonorrhea.
Products Worth Considering
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
Fitbit Versa 4 Fitness Smartwatch – Black/Graphite
As an affiliate, we earn on qualifying purchases.
New Entries and a C. difficile Shift
The updated list includes several additions and category changes. Drug-resistant N. meningitidis moved into the serious-threat category, while drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria joined the watch list. The report describes watch-list organisms as potential threats whose disease burden is uncertain and could merit further attention.
Clostridioides difficile, commonly called C. difficile, moved down from urgent to serious. The source report attributes that change in part to infection-prevention efforts and a decline in case numbers since 2011. A lower category does not mean the infection has ceased to pose a health risk; it reflects the CDC’s current assessment of threat level.
The report also notes two FDA approvals from the previous year: gepotidacin, marketed as Blujepa, and zoliflodacin, marketed as Nuzolvence, described in the source as the first new antibiotics for gonorrhea in decades. Their approval adds treatment options, but the report’s resistance figures show that drug-resistant gonorrhea remains a public-health concern.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Report’s Estimates
The supplied report summary gives the combined annual estimate of 9.7 million infections and 50,800 deaths, but does not specify the estimate’s calculation period or provide a breakdown of the total by pathogen. The 2023 figures for individual organisms are separate measures and should not be treated as directly comparable to the combined annual estimate without the report’s methods and definitions.
The watch-list pathogens have an uncertain disease burden, according to the source summary, and their addition does not establish how many infections or deaths they currently cause. The summary also does not provide the full criteria behind each category or detailed projections of future resistance. The precise effects of the newly approved gonorrhea antibiotics on resistance rates are not yet established in the information provided.
Policy and Surveillance Ahead
The CDC’s report calls attention to surveillance, infection prevention and the need for effective treatments, while the category changes give health agencies and care providers updated priorities to track. The source material does not identify a specific new CDC deadline or intervention tied to publication of the report.
Armstrong urged Congress to pass the PASTEUR Act, which would establish a federal program to support development of antimicrobial drugs for serious threats. According to the source report, versions of the bill remain stalled in congressional committees. Their next steps, and any action by Congress, remain uncertain.
Key Questions
What does the CDC estimate these pathogens cause each year?
The updated report estimates that the pathogens it tracks cause 9.7 million infections and 50,800 deaths annually in the United States. The supplied summary does not state the estimate’s calculation period or give a breakdown of the total by pathogen.
Which pathogens are classified as urgent threats?
The four urgent drug-resistant threats named in the report are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The source summary says C. difficile moved from urgent to serious, in part because infection-prevention measures have helped reduce case numbers since 2011. The change does not mean the infection is no longer a concern.
What is the CDC watch list?
It includes pathogens the agency regards as potential threats. The source says their disease burden is uncertain and could become a concern; inclusion does not establish a particular number of infections or deaths.
What is the PASTEUR Act?
It is proposed federal legislation that, according to the source report, would create a program to support development of antimicrobial drugs against serious pathogens and infections. The report says versions of the bill remain stalled in congressional committees.
Source: medpagetoday.com
